The Intersection of Prostate Cancer and Hypertension: a Call to Action.

Autor: Dolmatova E; Emory University School of Medicine, Atlanta, GA, USA., Waheed N; Emory University School of Medicine, Atlanta, GA, USA., Olson BM; Emory University School of Medicine, Atlanta, GA, USA., Patel SA; Emory University School of Medicine, Atlanta, GA, USA., Mandawat A; Emory University School of Medicine, Atlanta, GA, USA. anant.mandawat@emory.edu.; Cardio-Oncology Center of Excellence, Emory University, 1365B Clifton Rd NE Suite 4000, Atlanta, GA, 30322, USA. anant.mandawat@emory.edu.

Publikováno v: Current treatment options in oncology [Curr Treat Options Oncol] 2023 Jul; Vol. 24 (7), pp. 892-905. Date of Electronic Publication: 2023 May 16.

Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.

Autor: Ruggieri AN; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Yarchoan M; Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Goyal S; Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia., Liu Y; Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia., Sharon E; National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland., Chen HX; National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland., Olson BM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Paulos CM; Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia., El-Rayes BF; O'Neal Comprehensive Cancer Center of the University of Alabama at Birmingham, Birmingham, Alabama., Maithel SK; Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia., Azad NS; Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Lesinski GB; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Oct 03; Vol. 28 (19), pp. 4336-4345.

Sipuleucel-T: immunotherapy for advanced prostate cancer

Autor: Olson BM, McNeel DG

Publikováno v: Open Access Journal of Urology, Vol 2011, Iss default, Pp 49-60 (2011)

Brian M Olson, Douglas G McNeelUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USAAbstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::c30828b873bd624c332cf2bb07c9cff4
http://www.dovepress.com/sipuleucel-t-immunotherapy-for-advanced-prostate-cancer-a7329

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

Autor: Morel KL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Sheahan AV; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Burkhart DL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boufaied N; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada., Liu Y; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cañadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Roehle K; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Heckler M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Calagua C; Department of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Ye H; Department of Pathology, University of California at Los Angeles, Los Angeles, CA, USA., Pantelidou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Galbo P; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA., Panja S; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA., Mitrofanova A; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA.; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA., Wilkinson S; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Whitlock NC; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Trostel SY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kibel AS; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Einstein DJ; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., He HH; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Balk SP; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Labbé DP; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada.; Division of Urology, Department of Surgery, McGill University, Montréal, Canada., Olson BM; Departments of Hematology and Medical Oncology and Urology, Emory University School of Medicine, Atlanta, GA, USA., Ellis L; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. Leigh.Ellis@cshs.org.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Leigh.Ellis@cshs.org.; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Leigh.Ellis@cshs.org.; Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.

Publikováno v: Nature cancer [Nat Cancer] 2021 Apr; Vol. 2 (4), pp. 444-456. Date of Electronic Publication: 2021 Mar 22.

Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.

Autor: Zhang Y; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.; Department of Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China., Ware MB; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Zaidi MY; Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia., Ruggieri AN; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Olson BM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Komar H; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Farren MR; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Nagaraju GP; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Zhang C; Department of Biostatistics, Winship Cancer Institute of Emory University, Atlanta, Georgia., Chen Z; Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois., Sarmiento JM; Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia., Ahmed R; Emory Vaccine Center, Atlanta, Georgia., Maithel SK; Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia., El-Rayes BF; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. gregory.b.lesinski@emory.edu bassel.el-rayes@emoryhealthcare.org., Lesinski GB; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. gregory.b.lesinski@emory.edu bassel.el-rayes@emoryhealthcare.org.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Jan; Vol. 20 (1), pp. 150-160. Date of Electronic Publication: 2020 Oct 09.